About Qrativ
Qrativ is a Healthcare company based in Cambridge (United States) founded in 2017 by Murali Aravamudan and Andrew Badley. AI based drug purposing platform to identify treatments for rare diseases. Qrativ has raised $8.3 million across 1 funding round from investors including Matrix. Its chief executive, as recorded, is Murali Aravamudan. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Informatics. Its competitors include ScienceIO, Collaborative Drug Discovery and BioSymetrics; 2 of its 3 listed competitors have raised funding.
Company details
Qrative is a joint venture formed by Mayo Clinic nference to identify treatments for rare diseases using drug purposing approach. The company has developed a propriety drug purposing platform, Darwin.ai, leverages proprietary data from Mayo Clinics (EHRs, prescription diagnosis data, patient-treatment omics) and nferences knowledge synthesis AI platform (data extracted from PubMed, Clinical Trials, etc). The company claims that the drug developers can use its platform to identify uses for their molecules at an early phase of development. The company has got 8.3 million funding from Matrix Capital Management, Matrix Partners, and the Mayo Clinic.
- Headquarters Cambridge, United States
- Founders Murali Aravamudan, Andrew Badley
- SectorsHealthcare
- Website qrativ.bio
- Social LinkedIn
- Total Equity Funding$8.3M (USD)
in 1 rounds
- Latest Funding Round$8.3M (USD), Series A
Jul 2017
- Investors
Funding Insights of Qrativ
Qrativ has successfully raised a total of $8.3M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.3 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.3M
- Total Rounds 1
- Last Round Series A — $8.3M
- First Round $8.3M
(Jul 2017)
- Investors Count 1
All 1 funding rounds of Qrativ with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2017 | $8.3M | Series A | – | – |
1 investors in total: 1 institutional.
Investors in Qrativ
Qrativ has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Matrix.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage ventures are funded by the investment firm. | matrix.vc | San Francisco, United States |
Investor details for Qrativ
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Qrativ
2 people are tracked at Qrativ (2 in leadership).
| Name | Role | Group |
|---|---|---|
Murali Aravamudan | Co-Founder & CEO | Leadership |
Andrew Badley | Co-Founder | Leadership |
Complete people profiles for Qrativ
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Qrativ
2 dated milestones of Qrativ, from founding to its latest funding, stage changes and deals.
- Founded Qrativ is founded.
- Funding First funding round of $8.3M.
Competitors of Qrativ
Qrativ has 3 listed competitors in our database, 2 of them funded. They include ScienceIO, Collaborative Drug Discovery and BioSymetrics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| science.io | 2020 | Boston, United States | $8M | 22 | Provider of AI solutions transforming medical text into enriched healthcare data | |
| collaborativedrug.com | 2004 | Burlingame, United States | 31 | Biological and chemical data are managed securely in a database. | ||
| biosymetrics.com | 2015 | New York, United States | $4.88M | Provider of a cognitive computing-based biomedical intelligence platform |
Detailed competitors of Qrativ
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Qrativ (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Qrativ
Qrativ was founded in 2017.
Qrativ is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Murali Aravamudan is the CEO of Qrativ, as recorded in our data. They have also founded this company.
Qrativ is a funded company, having raised a total of $8.3M across 1 funding round to date. The company's 1st funding round was a Series A of $8.3M, raised on Jul 2017.
Qrative is a joint venture formed by Mayo Clinic nference to identify treatments for rare diseases using drug purposing approach. The company has developed a propriety drug purposing platform, Darwin.ai, leverages proprietary data from Mayo Clinics (EHRs, prescription diagnosis data, patient-treatment omics) and nferences knowledge synthesis AI platform (data extracted from PubMed, Clinical Trials, etc). The company claims that the drug developers can use its platform to identify uses for their molecules at an early phase of development. The company has got 8.3 million funding from Matrix Capital Management, Matrix Partners, and the Mayo Clinic.
Qrativ's top competitors include ScienceIO, BioSymetrics and Collaborative Drug Discovery.
Qrativ has 1 investor. Key investors include Matrix.